Innate Pharma reports first half 2022 financial results and business update
Innate Pharma announces conference call and webcast for first half 2022 business update
Innate Pharma to present lacutamab PTCL Phase 1b design and ANKET platform at ESMO 2022
Innate Pharma to participate in upcoming investor conferences
Number of shares and voting rights of Innate Pharma as of august 1, 2022
Innate Pharma provides update on AstraZeneca-sponsored Interlink-1 Phase 3 study
Innate Pharma to participate in upcoming investor conference
Second Innate Pharma NK Cell Engager Selected by Sanofi as drug candidate for development
Innate Pharma to participate in upcoming investor conference
Innate Pharma announces IPH5201 Phase 2 study in lung cancer
